EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation
Open Access
- 1 June 2010
- journal article
- Published by Elsevier BV
- Vol. 285 (24), 18575-18585
- https://doi.org/10.1074/jbc.m109.075085
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Targeting the mTOR Signaling Network for Cancer TherapyJournal of Clinical Oncology, 2009
- Protein kinase C beta in malignant pleural mesotheliomaAnti-Cancer Drugs, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteinsOncogene, 2008
- Cortactin in tumor invasivenessCancer Letters, 2008
- Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase PathwayPublished by Elsevier BV ,2008
- Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic statusClinical & Experimental Metastasis, 2006
- Eph receptor signalling casts a wide net on cell behaviourNature Reviews Molecular Cell Biology, 2005
- RETRACTED ARTICLE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinomaOncogene, 2004
- The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularizationOncogene, 2000